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Abstract: This study aims to determine the prevalence of asymmetric hearing loss 
(AHL) and late onset hearing loss (LOHL) in pediatric cancer patients treated 
with cisplatin and the risk factors for both AHL and LOHL.  This study will also 
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With the advances in treatment of pediatric cancer, the survival rate for children and 
adolescents has increased to over 80% (Bertolini et al., 2004; Siegal, Naishadhamc, & Jemal 
2013; Spix, Pastore, Gankila, Stiller, & Steliarova-Foucher, 2006).  Multimodality therapy has 
contributed to the increased survival rates in this patient population (Siegal, et al., 2013).  
Unfortunately, there are a number of adverse long-term effects due to cancer treatment that need 
to be identified and addressed.   
 
Risk Factors and Incidence of Platinum-induced Ototoxicity 
Ototoxicity or hearing loss is one of the major side effects of chemotherapy treatment 
with platinum compounds, such as cisplatin (CDDP) or high dose carboplatin (Coradini, Cigana, 
Selistre, Rosito, & Brunetto, 2007; Dean, et al., 2008; Knight, Kraemer, & Neuwelt, 2005; 
Punnet et al., 2004).  The presence and degree of ototoxicity varies in this population depending 
on a variety of factors.  In general, the most severe ototoxicity has been reported in patients 
receiving CDDP, while patients receiving only carboplatin alone have less risk of hearing loss 
(Dean et al., 2008).  Risk factors for developing hearing loss include: diagnosis at a younger age 
(especially younger than five years old), diagnoses such as central nervous system tumors and 
neuroblastoma, treatment with prior or concomitant cranial radiation, treatment with cumulative 
doses of cisplatin greater than 400 mg/m2, renal dysfunction, and pre-existing hearing loss.  
Other contributors to ototoxicity are the concomitant use of aminoglycoside antibiotics and loop 
diuretics (Grewal et al., 2010; Knight, Kraemer, Winter, and Neuwelt, 2007). 
The reported incidence of ototoxicity in pediatric oncology patients varies, ranging from 
as low as 4% to as high as 85% (Helt-Cameron & Allen, 2009; Dean, et al., 2008; Einarsson et 
al., 2010; Kolinsky, Hayashi, Karzon, Mao, & Hayashi, 2010; Kushner, Budnick, Kramer, 
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Modak, & Cheung, 2006; Massimino et al., 2010; Orgel et al., 2011).  This large range reflects a 
combination of factors, including: 1.) The age and developmental level of the patients studied 
necessitating the use of different testing modalities across the population, [auditory brainstem 
response testing (ABR), visual reinforcement audiometry (VRA), conditioned play audiometry 
(CPA), and/or conventional behavioral testing], influencing the observed rate of hearing loss; 2.) 
Different studies require different amounts and type of data for a patient to be evaluable; 3.) 
Varying definitions of hearing loss, including whether the better hearing ear, the worse ear, or 
averaged ear data is used to classify a patient; 4.) Varying age groups, influencing the reliability 
of testing; 5.) The unique challenges of the pediatric oncology patient, who are often not in ideal 
test states due to pain, sickness, fear, and/or fatigue, with the youngest patients constituting the 
most complicated ones.  Both the age and the state of the patient have an affect not only on the 
reliability of the test, but also the number of frequency thresholds obtained in each test session.   
Additionally, the inclusion of various types of hearing loss as a result of treatment can 
lead to a wide range of results.  Some studies include conductive and mixed hearing loss in the 
reported incidence of ototoxicity, while other studies solely link sensorineural hearing loss 
(SNHL) to the treatment (Brock et al., 2012; Jereczek-Fossa, Jarowski, Milani, & Orecchia, 
2003; Kolinsky et al., 2010).  Another factor contributing to the variability in incidence reports is 
that oto-protectant studies are often intermingled in the literature.  Studies clearly identifying 
patients with SNHL free of other confounding factors are rare.  Historically, a variety of grading 
scales have been used to report the incidence of ototoxicity, including the Brock grading scale, 
American Speech-Language-Hearing Association (AHSA) criteria, and the National Cancer 
Institute Cancer Therapy Evaluation Program’s Common Terminology Criteria for Adverse 
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Events (CTCAE) (Bass et al., 2014; Grewal et al., 2010).  All of these factors make comparing 
data across the literature difficult (Bass et al., 2014; Kolinsky et al., 2010).   
More recent attempts to standardize grading systems include the Society of Pediatric 
Oncology Boston Ototoxicity Grading Scale (SIOP) and the Chang grading systems.  These were 
developed to define pediatric sensorineural ototoxic hearing loss from platinum chemotherapies, 
with the goal to report the severity of hearing loss at the end of therapy and improve the 
correlation of the toxicity grade with functional outcomes.  Both scales are based on absolute 
hearing thresholds and focus on high frequency hearing loss, which is the characteristic pattern 
observed in patients receiving platinum based chemotherapy.  Authorities in the areas of oto-
protection have expressed the need for such grading systems to help standardize data across 
institutions and to improve the analysis of specific groups.  Such systems will aid in assessing 
the impact of oto-protectants (Brock et al., 2012).  A recent comparison of the SIOP and the 
Chang scale revealed that the SIOP scale appears to be more sensitive to identifying mild hearing 
losses and clinically significant hearing loss.  Furthermore, the SIOP scale has been reported to 
be easier to use and comprehend (Bass et al., 2014).   
 
Sensorineural Hearing Loss in Patients Treated with Platinum Compounds 
Hill and colleagues, (1972) were the first to report ototoxicity due to CDDP in adults.  
Hearing loss due to CDDP occurs due to damage to structures within the organ of Corti; CDDP 
specifically and simultaneously damages the outer hair cells and their associated stereocilia, 
spiral ganglion cells, and the stria vascularis (Schmidt, Knief, Lagosch, Deuster, & Zehnhoff-
Dinnesen, 2008; Schweitzer et al., 1984; Van Ruijven, de Groot, Klis, & Smoorenburg, 2005; 
Wright and Schaefer, 1982).  Deterioration of outer hair cells within the organ of Corti begins in 
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the basocochlear region, but damage can spread to the inner hair cells and lower frequency 
regions of the cochlea with continued exposure to platinum agents (Li, Womar, & Silber, 2004).  
Thus, platinum-induced hearing loss typically presents as a permanent, bilateral, usually 
symmetric, SNHL, with hearing loss beginning in the high frequencies (Blakey & Meyers 1993; 
Kushner et al., 2006; Schell et al., 1989).  The hearing loss may also be accompanied by 
peripheral neurotoxicity and permanent or temporary tinnitus (Alberts & Noel, 1995; Rybak, 
2005; Schmidt et al., 2008; Stavroulaki, Apostolopoulos, & Segas, Tsakanikos, & Adamopoulos 
2001).   
 
Hearing Loss in Children  
Acquired hearing loss in children and adolescents has a significant impact on 
communication, especially for young children who are developing or have not yet developed 
speech and language skills.  It is important to note that acquired and/or progressive SNHL can be 
a challenge to identify in the pediatric population due to the high prevalence of conductive 
hearing loss.  
Yoshinago-Itano, Sedey, Coulter, & Mel, (1998) demonstrated that hearing loss in 
children often leads to delays in speech and language.  Other reports have noted negative effects 
of hearing loss in children such as difficulties in auditory processing, communication, school 
performance, and social interaction, as well as reduced quality of life (QOL) measures (Barr et 
al., 2000; Bess, Dodd-Murphy, & Parker 1998; Knight et al., 2005; Moeller, Tomblin, 
Yoshinago-Itano, Connor, & Jerger, 2007).  The presentation of high frequency hearing loss 
associated with platinum-induced ototoxicity causes some consonants, mainly fricatives, to be 
inaudible.  Especially for young children, missing out on high frequency speech information 
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makes speech recognition and understanding particularly difficult (Knight et al., 2005; Li et al., 
2004; Stelmachowitz, Pittman, Hoover, Lewis, & Moeller, 2004).   
Gurney et al. (2007) observed that neuroblastoma patients with acquired hearing loss 
versus normal hearing were at least twice as likely to experience difficulties with reading skills, 
math skills, and/or attention issues and had a greater risk of having a general learning disability 
in addition to special educational needs.  Even mild high frequency hearing loss above 2,000 Hz 
has been correlated with increased fatigue in the classroom environment in addition to increased 
academic and social-emotional problems (Bess et al., 1998).  From a general pediatric 
perspective, Lieu (2004) reported that even a mild unilateral hearing loss (UHL) can have 
detrimental effects on a child’s language development as that child loses the typical advantages 
of hearing with both ears - localization abilities, loudness perception, enhanced speech 
perception, and improved ability to hear in noisy and quiet environments (Cadieux, Firszt, & 
Reeder, 2013; Ching, van Wanrooy, & Dillon, 2007).  Children with minimal and UHL are also 
at risk for speech and language, academic, and behavioral problems (Hindley, 1997; Stein, 
1983).  
It is important to note the fine distinction between UHL and asymmetric hearing loss 
(AHL), both of which are seen in the pediatric population.  UHL is used to describe a patient 
whose better-hearing ear is normal, while AHL is used when the better-hearing ear is impaired 
(Vila & Lieu, 2015).  UHL affects approximately three to six percent of school-age children in 
the United States (Ross, Visser, Holstrum, Qin, & Kenneson, 2010) and this percentage increases 
with age (Uwiera et al., 2009).  There is currently no documented prevalence of AHL because 
estimates for this type of loss are consolidated under the prevalence of bilateral hearing losses.  
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Recent estimates of any type of hearing loss (bilateral, UHL, AHL) in the adolescent population 
in the United States are approximately 20% (Shargorodsky, Curhan, Curhan, & Eavey, 2010). 
 
Current Study 
The literature substantiates that there is a critical need for early identification and 
intervention regarding any type (i.e., conductive or SNHL) and degree of hearing loss in children 
(Downs & Yoshinago-Itano 1999).  Monitoring air and bone conduction thresholds both during 
and after treatment is essential in the pediatric oncology population to provide the necessary 
services to ensure that children advance and develop normally (Bass, White, & Jones, 2013).  
Kolinsky et al. findings revealed that pediatric cancer survivors are at risk for hearing 
deterioration years after the cessation of chemotherapeutic therapy (2010).  Continued audiologic 
follow-up at regular intervals both during and long after the completion of therapy is crucial in 
order to identify and manage both chronic and late onset hearing loss (LOHL).   
It is well recognized that ototoxic hearing loss can present during the course of CDDP 
treatment (Li et al., 2004; Montaguti et al., 2002; Skinner, Pearson, Amineddine, Mathias, & 
Craft, 1990).  Less documented, but also reported, are auditory complications due to treatment 
with platinum compounds and radiotherapy that can progress beyond the cessation of treatment 
(Bertolini et al., 2004; Kolinsky, et al., 2010).  Whelan et al. (2011) reported that hearing loss 
due to cancer treatment could manifest or progress greater than five years following diagnosis.  
Similar results regarding worsening of auditory thresholds years after completion of treatment 
with CDDP were reported by Bertolini et al. (2004) and Einarsson et al. (2010) finding 
progressive hearing loss from 136 months to up to 22.3 years respectively.  For these reasons, 
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and because of the impact of hearing loss on a child’s global development, long-term follow-up 
beyond the completion of treatment is necessary. 
Another less documented, but significant complication in this patient population is AHL.  
Asymmetric and unilateral hearing losses due to treatment with CDDP and/or radiation have 
been reported in the literature (Aguilar-Markulis, Beckley, Priore, & Mettlin, 1981; Hayashi, 
Wheeler, King, Mansur, & Hayashi, 2014; Knight et al., 2007; Schmidt et al., 2008; Waters, 
Ahmad, Katsarkas, Stanimir, & McKay, 1991).  Schmidt et al. (2008) specifically found left ears 
to be significantly more affected in terms of high frequency hearing loss in patients receiving 
CDDP.  AHL, especially in patients with medulloblastoma or neuroblastoma, may also be linked 
to the development of LOHL in this population (Hayashi et al., 2014).  Given its impact on 
language and speech development, better characterization of AHL in pediatric patients is needed. 
The aim of this project is to determine the prevalence of AHL and LOHL in pediatric 
cancer survivors treated with CDDP.  Despite the extensive effort to investigate this topic, the 
variability in testing, the inconsistent or vague criteria for study subject entry, and the use of 
incomplete or ambiguous testing data leaves this field with many unanswered questions.  This 
effort will utilize stringent inclusion criteria to ensure the population analyzed has unambiguous 
clinical data so that clear interpretations of the test results and definitive conclusions can be 
rendered.  Preliminary data has suggested that patients with AHL are at increased risk for LOHL 
(Hayashi, et al., 2014).  We wish to expand our understanding of AHL and LOHL by examining 
an expanded cohort of childhood cancer survivors treated with CDDP. 
 
MATERIALS AND METHODS 
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This study was approved by the Institutional Review Board of the Washington University 
School of Medicine Human Research Protection Office.  It was a retrospective chart review of 
medical record data existing at the initiation of our study.  Audiology charts of pediatric 
oncology patients at St. Louis Children’s Hospital treated from August 1, 1990 through March 
31, 2015 were reviewed.  There were 993 patients in the entire cohort.  There were two arms to 
this study: 1.) Late onset hearing loss (LOHL) arm and 2.) Asymmetric hearing loss (AHL) arm.  
Eligibility criteria for both arms required prior CDDP treatment.  Patients whose routine medical 
care did not include CDDP were excluded up front.  These include the following diagnoses: 
retinoblastoma, sickle cell anemia, histiocytosis, acute lymphoblastic leukemia, acute myeloid 
leukemia, and juvenile myelomonocytic leukemia.  The remaining patient charts were reviewed 
for eligibility, identifying those patients who had a history of CDDP exposure, resulting in 248 
patients (Figure 1), none of which received oto-protectants any time during the course of their 
treatment.  The medical record of these patients were then reviewed to extract the following 
variables of interest: gender, birthdate, date of diagnosis, race, ethnicity, diagnosis, cumulative 
CDDP dose, presence of carboplatin and the corresponding cumulative dose, radiation exposure, 
radiation treatment to head, radiation treatment to the posterior fossa, proton beam radiation 
involving the head, the location of any radiation boost, date when all therapy ended, date of last 
CDDP administration, living status, date of last audiogram, and audiometric thresholds.  
 
Audiologic Methods  
Audiometric evaluations were performed by licensed audiologists from St. Louis 
Children’s Hospital.  All evaluations were completed according to the department of audiology’s 
clinical monitoring protocol for ototoxic induced hearing loss (Appendix A).  Pure-tone 
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thresholds were measured in a sound treated booth using a Grason Stradler two-channel clinical 
audiometer equipped with TDH39 headphones and ER-3A insert earphones.  Soundfield testing 
was used when headphones and insert earphones would not be tolerated.  The age, physical 
status and cooperation of the patient determined whether VRA, CPA, or conventional 
audiometry was used.  The time interval between audiologic evaluations as well as the number of 
evaluations varied between patients.  Air conduction thresholds recorded included 0.25, 0.5, 1, 
1.5, 2, 3, 4, 6, and 8 kHz.   
Every effort to generate and adhere to stringent criteria was made to eliminate exams that 
were ambiguous or could not be clearly classified.  Audiograms with predominantly conductive 
thresholds were not evaluable.  Eligible baseline audiograms had to have thresholds < 20 dB with 
at least two frequencies between 1 kHz - 4 kHz.  A “no response” threshold was logged as the 
highest threshold tested and negative thresholds were recorded as such.  Evaluable audiograms 
minimally had to have good to fair reliability.  
 The air-bone gap was evaluated to differentiate between a conductive hearing loss and a 
CDDP induced high frequency SNHL.  A threshold was not accepted if the air-bone gap 
difference was > 15 dBnHL.  Air-bone gaps of interoctaves were assumed to be < 10 dB and 
were evaluable if bone conduction was not tested as long as tympanometry indicated a normal 
middle ear status (a static admittance of > 0.3 mmho), a large canal volume consistent with 
patent tubes, or a normal otologic exam per an otolaryngologist.  A frequency specific threshold 
was not evaluable if there was a > 15 dB decrease from the previous audiogram, no bone line, 
and a static admittance < 0.2 mmho on tympanometry unless the audiograms on either side 
confirmed the sensorineural loss or there was a normal otologic exam by an examining 
otolaryngologist.  Any 6 kHz - 8 kHz hearing loss was assumed to be sensorineural if 
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tympanometry was > 0.3 mmho.  An audiogram with no change that had an absent tympanogram 
or a static admittance < 0.2 mmho was considered evaluable. 
Excluded patients were codified as follows: (1) incomplete audiologic data, (2) 
conductive hearing loss, (3), incomplete medical data, (4) patient currently receiving treatment, 
and (5) abnormal hearing at baseline. 
 
Criterion for assigning a patient for LOHL and/or AHL assessment 
We defined arbitrarily LOHL as a change in hearing greater than six months after 
completion of CDDP, to confidently identify changes in hearing that occurred long after CDDP 
had cleared the body.  Thus, to assess a patient for LOHL, they were required to meet the 
following criteria: Every patient had a normal baseline audiogram, and either two audiograms at 
least six months after the last CDDP administration or one earlier and one after the six month cut 
off with no change between the two, to fully classify the hearing state of the patient six months 
after CDDP therapy was complete.   
To assess a patient for AHL, the criterion was simpler as we included all patients who 
developed AHL regardless as to when it occurred.  Thus, only two audiograms were needed as 
we included patients where AHL could occur either during or after all therapy was completed. 
Thus, the eligibility criteria for AHL required that patients have at least a normal baseline with a 
subsequent ear specific audiogram conducted any time after the last CDDP administration or no 
baseline with a normal audiogram(s) conducted any time after the last CDDP administration.  
Soundfield audiograms were evaluable for the baseline audiogram as long as there was a 
subsequent ear specific audiogram.    
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Data from patient charts meeting the criteria above were evaluated through March 31, 
2015 as long as CDDP treatment was completed by that date.  A maximum of three audiograms 
was logged in the database for each patient.  The audiograms logged were placed into one of four 
subcategories: (a) baseline audiogram prior to CDDP therapy, (b) first audiogram after the last 
CDDP treatment but less than six months after treatment, (c) audiogram at least six months after 
CDDP treatment and (d) most recent evaluable audiogram when an audiogram meeting criteria 
(c) also existed.  The (b) audiogram was only logged when there were not at least two 
audiograms six months after the last CDDP and there was no change from the (b) to the (c) 
audiogram.  Our study allowed the baseline audiogram to be absent/abnormal if a subsequent 
audiogram documented normal hearing.  
In our study, a normal behavioral hearing test was defined as thresholds of < 20 dB from 
1 kHz - 4 kHz, and < 30 dB at 6 kHz to 8 kHz to account for tympanostomy tubes.  A normal 
ABR, at our institution was defined as thresholds of < 30 dBnHL from .5 kHz to 1 kHz and < 20 
at 2 kHz to 8kHz.  If any frequency was outside the defined normal range on the baseline 
audiogram, the audiogram for that ear was not evaluable.  If there was a normal baseline 
audiogram and sufficient data for only one ear, thresholds were collected; such patients were 
only evaluable for LOHL and not AHL.   
Each ear was assigned a SIOP classification relative to the bone conduction thresholds of 
the most recent audiogram.  Audiograms with a normal 4 kHz threshold but an absent or not 
evaluable 6 and 8 kHz threshold were codified as “not gradable test”, meaning that it could not 
utilize the SIOP classification.  For this study, SIOP grades 1 and 3 were based on at least one 
frequency referenced in the SIOP grade level.  This was due to the retrospective nature of the 
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present study and the fact that not all desired frequencies are always obtained in each test session 
with pediatric oncology patients. 
 
Classification for LOHL  
LOHL is defined as a significant change in hearing six months after the last CDDP 
administration.  The magnitude of the decrease was at least > 15 dB in one frequency from 1 kHz 
to 8 kHz, or a > 10 dB at two or more frequencies 1 kHz to 8 kHz in the same ear as compared 
with the previously entered audiogram.  Change was only evaluable if there was a bone line (in 
the audiogram being examined or another audiogram before or after) to confirm loss < 4 kHz.  If 
the loss was at or above 6 kHz, documentation was needed of a normal middle ear state through 
static admittance > .3 mmho, large canal volume consistent with patent tubes, and/or a normal 
otologic exam by an otolaryngologist.  Bone conduction thresholds always superseded 
tympanometric measures in the current study.  A decrease of < 10 dB at one evaluable frequency 
was not considered a significant change.  The patient’s final audiograms were coded as evaluable 
for LOHL, not evaluable for LOHL, positive for LOHL, or negative for LOHL. 
 
Classification for AHL  
AHL was arbitrarily defined as a threshold difference between ears of ≥ 20 dB at any one 
frequency 1 kHz and above, or ≥ 15 dB at two or more frequencies 1 kHz and above.  Each 
patient was coded as evaluable for AHL, not evaluable for AHL, positive for AHL (Figure 2), 
and negative for AHL.  
 
Statistical Methods  
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Patients were divided into three overlapping subsets, one with those evaluable for AHL, 
one with those evaluable for LOHL, and one evaluable for both AHL and LOHL.  In the first two 
subsets logistic regression was used to compare the odds of AHL or LOHL by diagnosis, 
radiation (any radiation, radiation to the head, radiation boost to the posterior fossa), gender of 
patient, age of patient at study baseline and at first CDDP exposure, concurrent exposure to 
carboplatin and cumulative CDDP dose.  A test for trend over an ordinal scale (Jonckheere’s 
test) was used to compare SIOP scores in the better or worst ears by presence of AHL or LOHL.  
In the third subset McNemar’s test was used to test for co-occurrence of AHL and LOHL.  All 
analyses were carried out using SAS/STAT v14.1 for Windows. 
 
RESULTS 
Of the 993 patients in the entire database, 248 patients received CDDP and their medical 
records were reviewed.  One-hundred and thirty-six patients met the eligibility criteria for 
inclusion in the AHL study, while 112 patients met the eligibility criteria for inclusion in the 
LOHL study.  Criterion for exclusion for the AHL study included: 1.) Incomplete audiologic data 
(n = 69), 2.) Incomplete medical data (n = 4), 3.) Conductive hearing loss (n = 4), 5.) Patient 
actively treated (n =7), 6.) Possessed an ear with an abnormal baseline (n = 27).  Criterion for 
exclusion of the LOHL study included: 1.) Incomplete audiologic data (n = 108), 2.) Incomplete 
medical data (n = 4), 3.) Patient actively treated (n = 7), 4.) Possessed an ear with an abnormal 
baseline (n = 16).   
Table 1 summarizes the patient characteristics for those included in each study.  Each of 
the study populations are representative of the general cancer population treated at Saint Louis 
Children’s Hospital – a predominantly Caucasian patient demographic with a slight male 
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predominance.  The cancer diagnoses reflect populations typically treated with CDDP using 
standard treatment regimens. Some patients also received carboplatin and/or radiation therapy 
which are also known to be ototoxic.   
 
LOHL 
There were 64 males and 48 females included in the LOHL study.  87 (78%) patients had 
CDDP only, while 25 (22%) had a combination of CDDP and carboplatin.  50 (45%) patients 
had radiation treatment to the head as part of their treatment.  Of the 112 patients that met the 
eligibility criteria, 47 (42%) exhibited LOHL.  
The observed risk of LOHL differed by diagnosis (p = .03).  The odds of LOHL were 
70% - 80% lower in patients with osteosarcoma and patients with other solid tumors compared to 
those with a diagnosis of medulloblastoma.  Odds ratios are osteosarcoma versus 
medulloblastoma 0.21 (0.056, 0.76) and other solid tumors versus medulloblastoma 0.30 (0.099, 
0.93).  At their most recent audiogram, patients with medulloblastoma had higher SIOP scores in 
both the better ear (p = .0023) and worse ear (p = .021) compared to the other tumors types in 
this arm of the study, further illustrating the vulnerability of patients with this cancer diagnosis.   
The features of patients with and without LOHL are summarized in Table 2.  Radiation is 
a major risk factor for LOHL with a nearly five fold increased risk compared to those who did 
not receive radiation as part of their therapy (odds ratio = 4.9 (2.0, 11.8), p =.0004).  Having 
radiation to the head increased the odds of LOHL 2.5 times (odds ratio = 2.5 (1.1, 5.3), p = .022).     
Furthermore, radiation boost to the posterior fossa, which contains the cochlea in the field, also 
associated with an increased risk of LOHL (odds ratio = 2.5, p = .037).  There is no evidence that 
gender, the addition of carboplatin, or the total cumulative exposure of CDDP are associated 
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with an increased risk of LOHL.  There is also no evidence of a significant difference in SIOP 
scores between ears. 
Older age appears to be protective against LOHL.  The odds of LOHL decrease 
by 12% for each 1-year increase in the age at baseline hearing exam or age at diagnosis 
(odds ratio = .88 (0.82, 0.96) in each case, p-values are .0016 and .0014 for age at the 
baseline hearing exam and age at diagnosis, respectively). 
Figure 3 plots patients with LOHL verses the time interval from the end of CDDP 
treatment to the last audiogram of the study and compares those patients without LOHL.  
Patients with LOHL were associated with a longer follow-up (median 55 months) compared to 
those without LOHL (median 30 months).   This association was maintained even when the time 
interval from the completion of all therapy to the last audiogram of the study was plotted. Thus, 
patients with the longest follow-up were more likely to display findings consistent with LOHL.  
 
AHL  
Table 2 displays the features of the patients who fulfilled eligibility criterion to assess for 
AHL.  There were 78 males and 58 females included in the AHL study.  Ninety-eight (72%) 
patients had CDDP, while 38 (28%) had a combination of CDDP and carboplatin.  Fifty-one 
(37.5%) patients had radiation treatment to the head in addition to CDDP.  Of the 136 patients 
that met the eligibility criteria 35 (26%) exhibited AHL.  
The odds of AHL are lower for all diagnoses relative to medulloblastoma (p = .003).  For 
instance, the odds are about 90% lower among patients with ‘other solid tumors’ (including germ 
cell tumors and hepatoblastomas odds ratio = .071 (0.014, 0.35)), about 80% lower among 
patients with osteosarcoma (odds ratio = 0.20 (0.066, 0.63)) and non-medulloblastoma brain 
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tumors (odds ratio = 0.19 (0.045, 0.79)), and about 70% lower among neuroblastoma patients 
(odds ratio = .29 (0.098, 0.88)).  Similar to the LOHL study, SIOP scores at the most recent 
audiogram are highest, in both better and worse ears, in medulloblastoma patients than in 
patients with other tumors (in the better ear p = .0003, in the worst ear p = .0067).  There is no 
evidence that SIOP scores were preferentially worse in one ear (left versus right) even when 
factoring diagnoses. 
AHL treatment characteristics are summarized in Table 3.  Radiation is also associated 
with an increased risk of AHL.  A history of radiation as part of the patient’s treatment increased 
the odds of AHL by 2.5 times (1.1, 5.9), p = .034), while radiation to the head increased the odds 
by 2.6 times (1.2, 5.6, p = .019), and a radiation boost specifically to the posterior fossa increased 
the odds of AHL by 3.8 times (1.6, 9.1), p = .0025).  There is no evidence that any other factor 
examined including gender, age at diagnosis, or the use of carboplatin with cisplatin is associated 
with greater odds of AHL (p = .98 for gender, p = .59 for carboplatin).  
 
AHL as a Predictor of LOHL 
Given the similarities in risk factors for developing AHL and LOHL, we examined 
whether there was a relationship between these two clinical entities. This required the generation 
of an additional dataset, ensuring that the criterion for both AHL and LOHL was present for the 
same patients, since there were some patients that were assessable for one and not the other.  
Ninety-six of the 248 were eligible for both AHL and LOHL studies, of which 35 were positive 
for AHL and 47 were positive for LOHL.  Twenty-one of the 96 included in both studies were 
positive for both AHL and LOHL (Figure 4).  The diagnoses of patients who were positive for 
both AHL and LOHL included: medulloblastoma (n = 10), neuroblastoma (n = 5), osteosarcoma 
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(n = 2), choroid plexus carcinoma (n =1), hepatoblastoma (n =1), germinoma (n =1), and 
nasopharyngeal carcinoma (n =1), which is representative of the original distribution of 
diagnoses in the AHL and LOHL studies.  
AHL does appear to be strongly associated with LOHL.  Seventy-five percent of patients 
with AHL also had LOHL.  Similarly, those patients with no AHL also had a low incidence of 
LOHL (28%). 
McNemar’s test also concludes that AHL tends to occur with LOHL and no AHL was 
associated with the absence of LOHL (p = .019).   
A logistic regression of LOHL was calculated, revealing that both radiation and AHL are 
independently significant as risk factors for LOHL.  The odds of LOHL are about 6 times greater 
in patients with AHL than those without (odds ratio = 6.3 (2.2, 17.8), p = .0005), after taking into 




 Serious developmental consequences stem from the presence of hearing loss in the 
pediatric population, namely its effects on speech, language, social skills, listening skills, and 
learning to read and write.  Hearing loss also affects the structures in the brain associated with 
the auditory system; the brain needs to be able to hear sound in order to make sense of it.  
Without the incoming stimulation, the auditory centers of the brain are not being properly 
stimulated and developed (Merzenich, 2010).  
 This investigation demonstrates that individuals receiving CDDP therapy are at risk for 
developing both LOHL and AHL.  LOHL and AHL are relatively under-appreciated 
complications in the current literature regarding pediatric cancer survivors, yet this report 
suggests that they affect a significant percent of those receiving platinum based therapy.   
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 In this study, we characterized the prevalence and risk factors of LOHL and AHL with 
the longest follow-up consisting of 208 months (17 years).  The data analysis revealed that 
LOHL is a frequent complication of patients receiving CDDP, with almost half of the patients 
developing LOHL, and that radiation and diagnosis are significant risk factors.  A high 
prevalence was also observed in the AHL cohort, with almost one-third of the patients 
developing AHL.  Further analysis revealed that those patients who either developed AHL and/or 
received radiation treatment were at an increased risk (Odds Ratio = 2.7) for LOHL.  Physicians 
and audiologists should be aware of these findings in order to be able to identify affected patients 
early and recognize the critical need for vigilant, long term follow-up as many appear to have 
worsening hearing with time.   
 This study is unique due to the rigor of data included in the analysis.  Patients were only 
included if they had a normal baseline audiogram, if bone conduction thresholds were recorded 
to confirm the sensorineural nature of the hearing loss, and if their audiograms had good to fair 
reliability.  Patients were excluded if they had incomplete audiologic data (i.e., poor reliability, 
bone conduction not tested, insufficient number of audiograms for analysis), a conductive 
hearing loss, incomplete medical data, and if they were currently being treated at the time of the 
study.  Previous studies have failed to use this level of criterion, for example, often mixing 
patients with conductive hearing losses into their study population.  The stringent criteria utilized 
in this study allows for a more reliable estimate of the prevalence of LOHL and AHL and their 
associated risk factors. 
The findings in the current study provide significant information to guide clinicians in the 
management of this patient population.  The present study spans the full scope of ages and 
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diagnoses in the pediatric oncology population and indicates that both AHL and LOHL affect a 
significant fraction.  
One of the reasons AHL may be under-appreciated in the literature is due to the 
assumption that ototoxicity from treatment with platinum compounds results in systemic 
exposure in which clinicians would expect a bilateral, symmetric hearing loss.  The presence of 
AHL needs to be recognized and identified as a serious complication after chemotherapeutic 
treatment, given its potential impact on this population.  Children with AHL may have 
difficulties in communicating, fail to achieve developmental milestones, understanding speech in 
noisy settings, learning in classroom settings, and locating sounds (Vila & Lieu, 2015).  
Behavioral issues have also been reported in children with AHL in addition to lower levels of 
self esteem and higher levels of exhaustion and stress due to the increased effort put in to simply 
trying to listen (Bess et al., 1998; Ross, Gaffney, Green, & Holstrum, 2008).  Not specific to the 
AHL literature, but of significance, are the findings of Orgel et al. (2016); the group examined 
pediatric brain tumor survivors and found that those with SNHL were at an increased risk for 
noteworthy neurocognitive and intellectual deficits.  In terms of hearing aid fitting in patients 
with AHL, it is important for the audiologist to recognize that there is not balanced hearing from 
both sides and that certain steps during hearing aid programming must be taken to give the 
patient the best unified incoming signal possible.    
Given today’s long term survival rates in pediatric cancer patients and the continued 
identification of LOHL with increased length of follow-up, continued monitoring of these 
patients is essential for the earliest intervention as hearing deteriorates.  Close monitoring will 
also be critical in terms of the possible need to reprogram the patient’s hearing aids, i.e., 
providing more amplification, especially with the known risk of progressive hearing loss in 
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certain populations.  Additionally, it is important for the audiologist to counsel these patients on 
the effects of harmful levels of noise, (i.e., from concerts and other loud recreational activities) 
as high levels of noise have been reported to potentiate CDDP-induced hearing loss (Peleva, 
Aloy, Carret, & Daniel, 2014; Steyger, 2009).  One study revealed that even a mild noise 
exposure during CDDP treatment significantly increases risk of permanent hearing loss.  Even 
when the CDDP caused no ototoxicity, they found that the interaction of noise and non-ototoxic 
doses of CDDP could cause a significant hearing loss.  The study advances the need for strict 
audiological monitoring and counseling for the possibility of increased susceptibility of 
permanent hearing loss from noise exposure both during and after treatment with CDDP 
(Boettcher, Henderson, Gratton, Danielson, & Byrne, 1987).  
 There were limitations of this study.  It is a retrospective chart review, in which there was 
a lack of regimented serial monitoring as patients were tested in variable intervals.  Patients who 
were lost to follow-up or had incomplete audiologic data could not be accounted for.  Many 
patients were excluded from this study due to the exceptionally strict inclusion criteria that was 
implemented.  Also, all ototoxic agents that could have an additional affect on the hearing levels 
of the patients examined were not taken into account; only carboplatin, CDDP, and radiotherapy 
information was collected.  Despite these limitations, this study illustrates the importance of 
close monitoring of this patient population.  
 
CONCLUSION 
The clinical implications for the current study are that regular follow up is critical in 
patients treated with cisplatin and radiation therapy to identify patients with LOHL and AHL.  
Patients with certain diagnoses are at an even higher risk for developing AHL and LOHL, and 
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AHL was a risk factor for developing LOHL.  The presence of AHL should be a red flag for 
clinicians that these patients’ hearing loss may get progressively worse long after the completion 
of treatment.  Future studies are needed to assess the impact of LOHL and AHL on the long term 
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      Demographics: All Eligible Patients  
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LOHL indicates late onset hearing loss. CDDP indicates cisplatin. 
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TABLE 3  



































Reviewed charts of pediatric oncology patients at St. Louis Children’s Hospital treated from August 1, 
1990 through March 31, 2015.  993 patients in the entire cohort. 2 arms to this study: 1.) LOHL arm 2.) 
AHL arm.  Patients must have been treated with cisplatin to be included. Reviewed patient charts, 



























Example audiogram of AHL. Defined in present study as a threshold difference 
between ears of ≥ 20 dB at any one frequency 1 kHz and above, or ≥ 15 dB at 



























Patients with & without LOHL verses the time interval from the last 
cisplatin treatment to the most recent audiogram.  Patients with LOHL 
were associated with a longer time interval versus those without 
LOHL.  This association held true even when plotting the time period 


























96 of 248 were eligible for AHL & LOHL studies, 35 were positive for AHL; 47 were 
positive for LOHL.  21 of the 96 included were positive for both AHL and LOHL. 
Diagnoses of patients positive for both include: medulloblastoma (n = 10), neuroblastoma 
(n = 5), osteosarcoma (n = 2), choroid plexus carcinoma (n =1), hepatoblastoma (n =1), 




St. Louis Children’s Hospital  
Audiologic Assessment/Monitoring of Hematology/Oncology Patients 
Initial Behavioral Hearing Test Protocol  
a) Pure tone thresholds 250 Hz-8KHz with bone if needed. Begin at 1 or 2KHz and above. 
Include 3K and 6KHz if possible.  Use 3A inserts as long as ears are cleared of wax and 
if patient tolerates wearing them. Log the type of transducer used.   Note on audiogram 
if IVAC is in sound suite. 
b) Tympanometry 
c)  Speech recognition testing if possible. Standardized presentation if possible. 
d)  OAE’s if a brain tumor patient has a sensorineural asymmetry. 
NOTE: Ultrahigh frequencies are no longer tested as of 2010. 
e) If consistent, reliable responses could not be obtained, recommend “sedated ABR if 
current thresholds are needed.” The hem/onc medical team will schedule as 
appropriate. 
Initial ABR Hearing Test Protocol 
a) Click, 4KHz, 8KHz, 2KHz, 1KHz and 500 Hz if possible. 
b) Include OAEs if possible, especially for brain tumors. 
c) Tympanometry as needed if possible. 




a) Look for previous audiologist notes and meeting notes. Notes will be in Clin 
Desk>Notes>Progressnotes>Audiology progress notes. It is important to know where the 
patient is in their treatment course before making recommendations.   
b) Follow-up protocols are the same as the initial protocols except for speech recognition, 
which is not tested unless a significant change is noted in hearing sensitivity. Always test 
both ears, including B/C, even if one is profound. 
Follow-up Protocol Recommendations: (Still on chemotherapy) 
1) If no change from previous hearing test and normal tympanogram: 
1) Follow-up per protocol or managing physician or sooner if change is noted 
or if tinnitus is experienced. 
2) Noise precautions (music, hunting, work, recreation) 
2) If  no change from previous hearing test but abnormal tympanogram: 
1) Follow up per protocol or managing physician or sooner if change is noted 
or if tinnitus is experienced 
2) Noise precautions ( music, hunting, work, recreation) 
3) Otologic exam by managing physician. 
3) If conductive hearing loss (inpt/outpt): 
1) Call 4-6018 and ask for patient’s clinical nurse coordinator (CNC) or 
nurse practitioner, explain results and ask if they can be seen. If patient is 
going home or has no available time the rest of the day, after appointment, 
send a CNC group e-mail informing them of loss and recommendations. 
Include this information in patient’s progress notes to be scanned. 
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2) Recommend otologic management with managing hem/onc team and 
follow up per protocol. 
4) If change in conventional frequencies (inpt/outpt): 
ONE OF 3 SITUATIONS: 
1) If patient is receiving chemo that day,call 4-6018 after the patient 
leaves to speak with the patient’s clinical nurse coordinator (CNC) or 
nurse practitioner.  Explain results, write the disposition in patient’s 
progress notes to be scanned.  
2) If they are still receiving therapy, but not that day, send an e-mail by 
the end of the day to the CNC group e-mail. Write in patient’s 
progress notes that an e-mail was sent to the CNC group e-mail for 
scanning. 
3) If patient is post therapy, the significant change can just be noted on 
the audiogram (because there is no therapy to be changed). Follow Post 
Treatment recommendations on next page as well as any additional 
standard audiologic recommendations. 
5) If hearing loss impacts speech understanding: 
1) See if previous notes began the discussion with family or medical team.  If 
hearing aids have been broached, chemotherapy treatment is complete and 
the medical team advised audiology to proceed, counsel/schedule 
appropriately.  
2) If no previous discussions have occurred, send a group CNC e-mail to see 
if amplification is appropriate at this time both for the patient and the 
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family. Write a chart note and scan.  It is important for the medical team to 
understand the intent of the recommendation and what is involved in the 
process. If this is not a good time, inform them that loaners and a pocket 
talker are available. Ask if it is an appropriate time to move forward with a 
speech/language evaluation as well.  
Post Treatment Recommendations: 
6) When cranial irradiation only (without being combined with ototoxic drugs) 
has ended: 
                           a) If hearing is normal 2 years post therapy, a hearing test is recommended  
      only if hearing or school concerns arise.   
7) When cisplatin with or without carboplatin treatment has ended:   
1) Hearing tests at 3,6,12 months and annually 
2) Noise precautions 
3) Speech /language evaluation as needed but especially for those with 
hearing loss. 
8) When Carboplatin with or without radiation has ended: 
1) Annually until they reach 10 years of age or 5th grade or are able to 
reliably self report.  
2) NF and Retinoblastoma patients will be tested annually. 
9) Post Bone Marrow Transplants: (With no previous treatments) 
1) Hearing is tested at the 110 day marker (~3 months). If hearing is 
normal, a follow-up test is recommended at 1 year post transplant. If 
hearing is normal at the second year audiogram, further hearing test 
Swindall 
 43 
are recommended only if concerns arise.  If a hearing loss exists at the 
100 day marker, recommendations are the same as the cisplat follow 
up above. 
2) If patient has had previous chemo treatments, follow 
recommendations 7 or 8 above.  
Sickle Cell Patients (Chronically transfused and on chelation therapy (exjade/desferol) and 
monitoring of hearing is ongoing) 
(1)  Annual audiograms or sooner if hearing or school concerns arise. 
(2) Word recognition and speech-in-noise testing should be done at each annual 
hearing evaluation.  
Late Effects Patients (Some were treated at SLCH – some were not) 
Follow the Post Treatment Recommendations (6/7/8/9) above.  
Hearing aids if appropriate. If families have financial difficulties, funding packets are 
available.  Center for Hearing and Speech has funding programs and scholarships as well. For 
those patients whose hearing aids are managed at outside facilities, a hearing aid check will 
be recommended by the Late Effects team prior to receiving a Neuropsychological 
evaluation. This is to ensure that the aids are functioning and offering appropriate gain. 
 
Put a copy of all hem/onc patient audiograms in the envelope (outpts/inpts, h/a pts, CAP 
pts, ENT pts, sickle cell pts, late effects pts) in Sue Hayashi’s mailbox.  The patients will be 
reviewed, discussed at the hem/onc meetings and chart notes written on each patient. All 




If the patient is an inpatient, place a copy of the results in the inpatient chart and 
remember to enter the test results into his/her KIDDOS chart. 
 
Hearing test paperwork is scanned the same day.  The Orange Hem/Onc Scan folder is 
currently behind the fee sheet bin at the Audiology Registrars’ desk. 
 
Written by/Effective Date: S. Hayashi 1/06 
Reviewed by Date: S. Hayashi, P. Koprowski 
Revised by Date: S. Hayashi, P. Koprowski 4/2015 




     
 
 
 
 
 
 
 
 
 
